iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. (ITOS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ITOS · as of Jun 9, 2026
Activity summary
Buy transactions
3
P-Purchase only
Sell transactions
16
12 Months
Buy/Sell ratio
0.19
Buy/Sell (by trades)
Overall sentiment
iTeos Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
ITOS insider buying and selling by quarter
ITOS insider selling · ITOS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · ITOS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ITOS executive sell shares · ITOS board member insider trading · ITOS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Aug 29, 2025 | Call Matthew COO | Other | 161,898 | $1.63M⚡ | Form 4 |
| Aug 29, 2025 | Detheux Michel CEO · Director | Other | 94,027 | $945K | Form 4 |
| Aug 29, 2025 | Feltquate David Chief Medical Officer | Other | 47,000 | $472K | Form 4 |
| Aug 29, 2025 | Gall Matthew CFO | Other | 89,429 | $898K | Form 4 |
| Aug 29, 2025 | McGrath Yvonne Chief Scientific Officer | Other | 46,300 | $465K | Form 4 |
| Jun 10, 2025 | Detheux Michel CEO | Option | 18,000 | $77K | Form 4 |
| Jun 10, 2025 | Detheux Michel CEO | Option | 8,400 | $36K | Form 4 |
| Jun 9, 2025 | Detheux Michel CEO | Sale | 8,400 | $84K | Form 4 |
| Jun 10, 2025 | Detheux Michel CEO | Sale | 8,400 | $84K | Form 4 |
| Jun 10, 2025 | Detheux Michel CEO | Option | 94,027 | $404K | Form 4 |
| Jun 10, 2025 | Detheux Michel CEO | Option | 43,883 | $189K | Form 4 |
| Jun 9, 2025 | Detheux Michel CEO | Option | 43,882 | $189K | Form 4 |
| Jun 10, 2025 | Detheux Michel CEO | Sale | 43,883 | $440K | Form 4 |
| Jun 9, 2025 | Detheux Michel CEO | Sale | 43,882 | $440K | Form 4 |
| Jun 6, 2025 | Detheux Michel CEO | Option | 8,400 | $36K | Form 4 |
| Jun 6, 2025 | Detheux Michel CEO | Sale | 8,400 | $86K | Form 4 |
| Jun 4, 2025 | Detheux Michel CEO | Sale | 8,400 | $85K | Form 4 |
| Jun 5, 2025 | Detheux Michel CEO | Sale | 8,400 | $85K | Form 4 |
| Jun 4, 2025 | Detheux Michel CEO | Option | 43,883 | $189K | Form 4 |
| Jun 6, 2025 | Detheux Michel CEO | Option | 43,882 | $189K | Form 4 |
| Jun 6, 2025 | Detheux Michel CEO | Sale | 43,882 | $448K | Form 4 |
| Jun 4, 2025 | Detheux Michel CEO | Sale | 43,883 | $443K | Form 4 |
| Jun 5, 2025 | Detheux Michel CEO | Sale | 43,882 | $445K | Form 4 |
| Jun 6, 2025 | Hallal David Director | Option | 38,228 | $164K | Form 4 |
| Jun 5, 2025 | Hallal David Director | Option | 38,227 | $164K | Form 4 |
Feltquate David
Chief Medical Officer
Date
Aug 29
Shares
47,000
Price
$10.05
Value
$472K
McGrath Yvonne
Chief Scientific Officer
Date
Aug 29
Shares
46,300
Price
$10.05
Value
$465K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ITOS insider trading
ITOS insider trades
iTeos Therapeutics, Inc. (ITOS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Detheux Michel (CEO · Director), Call Matthew (COO), Feltquate David (Chief Medical Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. ITOS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For iTeos Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ITOS insider trading · 5 questionsThe insiders of iTeos Therapeutics, Inc. (ITOS) include executives and directors such as Detheux Michel (CEO · Director), Call Matthew (COO), Feltquate David (Chief Medical Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026